Carisma Therapeutics announces first patient dosed in landmark clinical study evaluating engineered macrophages in humans

Clinical stage biopharmaceutical company, CARISMA Therapeutics Inc., announced that the first patient has been dosed in the Phase 1 multi-center clinical trial for CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M).

Article from Carisma Therapeutics